Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
Background. The use of gemcitabine as an adjuvant modality for cholangiocarcinoma (CC) is increasing, but limited data are available on predictive biomarkers of response. Human equilibrative nucleoside transporter 1 (hENT‐1) is the major transporter involved in gemcitabine intracellular uptake. This...
Saved in:
Published in | The oncologist (Dayton, Ohio) Vol. 21; no. 5; pp. 600 - 607 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Durham, NC, USA
AlphaMed Press
01.05.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background.
The use of gemcitabine as an adjuvant modality for cholangiocarcinoma (CC) is increasing, but limited data are available on predictive biomarkers of response. Human equilibrative nucleoside transporter 1 (hENT‐1) is the major transporter involved in gemcitabine intracellular uptake. This study investigated the putative predictive role of hENT‐1 localization in tumor cells of CC patients undergoing treatment with adjuvant gemcitabine.
Methods.
Seventy‐one consecutive patients with resected CC receiving adjuvant gemcitabine at our center were retrospectively analyzed by immunohistochemistry for hENT‐1 localization in tumor cells. The main outcome measure was disease‐free survival (DFS). Hazard ratios (HRs) of relapse and associated 95% confidence intervals (CIs) were obtained from proportional hazards regression models stratified on quintiles of propensity score.
Results.
Twenty‐three (32.4%) cases were negative for hENT‐1, 22 (31.0%) were positive in the cytoplasm only, and 26 (36.6%) showed concomitant cytoplasm/membrane staining. Patients with membrane hENT‐1 had a longer DFS (HR 0.49, 95% CI 0.24–0.99, p = .046) than those who were negative or positive only in the cytoplasm of tumor cells. Notably, the association between DFS and membrane hENT‐1 was dependent on the number of gemcitabine cycles (one to two cycles: HR 0.96, 95% CI 0.34–2.68; three to four cycles: HR 0.99, 95% CI 0.34–2.90; five to six cycles: HR 0.27, 95% CI 0.10–0.77).
Conclusion.
hENT‐1 localization on tumor cell membrane may predict response to adjuvant gemcitabine in CC patients receiving more than four cycles of chemotherapy. Further prospective randomized trials on larger populations are required to confirm these preliminary results, so that optimal gemcitabine‐based chemotherapy may be tailored for CC patients in the adjuvant setting.
Implications for Practice:
Gemcitabine is becoming an increasingly used adjuvant modality in cholangiocarcinoma (CC), but limited data are available on predictive biomarkers of response. In this study, patients receiving more than four cycles of adjuvant gemcitabine and harboring Human equilibrative nucleoside transporter 1 (hENT‐1, the major transporter involved in gemcitabine intracellular uptake) on tumor cell membrane had a longer disease‐free survival compared with patients negative or positive for hENT‐1 only in the cytoplasm of tumor cells. Overall these results may lay the basis for further prospective randomized trials based on a larger population of patients and may prove useful for tailoring appropriate gemcitabine‐based chemotherapy for CC patients in the adjuvant setting.
In patients with resected cholangiocarcinoma undergoing treatment with adjuvant gemcitabine, human equilibrative nucleoside transporter 1 (hENT‐1) localization within tumor cells may be negative, positive in the cytoplasm only, or positive in both cytoplasm and membrane. Patients with hENT‐1 in membrane had longer disease‐free survival than the other groups, and the prediction was stronger with more cycles of gemcitabine. |
---|---|
AbstractList | In patients with resected cholangiocarcinoma undergoing treatment with adjuvant gemcitabine, human equilibrative nucleoside transporter 1 (hENT-1) localization within tumor cells may be negative, positive in the cytoplasm only, or positive in both cytoplasm and membrane. Patients with hENT-1 in membrane had longer disease-free survival than the other groups, and the prediction was stronger with more cycles of gemcitabine. Abstract Background. The use of gemcitabine as an adjuvant modality for cholangiocarcinoma (CC) is increasing, but limited data are available on predictive biomarkers of response. Human equilibrative nucleoside transporter 1 (hENT-1) is the major transporter involved in gemcitabine intracellular uptake. This study investigated the putative predictive role of hENT-1 localization in tumor cells of CC patients undergoing treatment with adjuvant gemcitabine. Methods. Seventy-one consecutive patients with resected CC receiving adjuvant gemcitabine at our center were retrospectively analyzed by immunohistochemistry for hENT-1 localization in tumor cells. The main outcome measure was disease-free survival (DFS). Hazard ratios (HRs) of relapse and associated 95% confidence intervals (CIs) were obtained from proportional hazards regression models stratified on quintiles of propensity score. Results. Twenty-three (32.4%) cases were negative for hENT-1, 22 (31.0%) were positive in the cytoplasm only, and 26 (36.6%) showed concomitant cytoplasm/membrane staining. Patients with membrane hENT-1 had a longer DFS (HR 0.49, 95% CI 0.24–0.99, p = .046) than those who were negative or positive only in the cytoplasm of tumor cells. Notably, the association between DFS and membrane hENT-1 was dependent on the number of gemcitabine cycles (one to two cycles: HR 0.96, 95% CI 0.34–2.68; three to four cycles: HR 0.99, 95% CI 0.34–2.90; five to six cycles: HR 0.27, 95% CI 0.10–0.77). Conclusion. hENT-1 localization on tumor cell membrane may predict response to adjuvant gemcitabine in CC patients receiving more than four cycles of chemotherapy. Further prospective randomized trials on larger populations are required to confirm these preliminary results, so that optimal gemcitabine-based chemotherapy may be tailored for CC patients in the adjuvant setting. Background. The use of gemcitabine as an adjuvant modality for cholangiocarcinoma (CC) is increasing, but limited data are available on predictive biomarkers of response. Human equilibrative nucleoside transporter 1 (hENT‐1) is the major transporter involved in gemcitabine intracellular uptake. This study investigated the putative predictive role of hENT‐1 localization in tumor cells of CC patients undergoing treatment with adjuvant gemcitabine. Methods. Seventy‐one consecutive patients with resected CC receiving adjuvant gemcitabine at our center were retrospectively analyzed by immunohistochemistry for hENT‐1 localization in tumor cells. The main outcome measure was disease‐free survival (DFS). Hazard ratios (HRs) of relapse and associated 95% confidence intervals (CIs) were obtained from proportional hazards regression models stratified on quintiles of propensity score. Results. Twenty‐three (32.4%) cases were negative for hENT‐1, 22 (31.0%) were positive in the cytoplasm only, and 26 (36.6%) showed concomitant cytoplasm/membrane staining. Patients with membrane hENT‐1 had a longer DFS (HR 0.49, 95% CI 0.24–0.99, p = .046) than those who were negative or positive only in the cytoplasm of tumor cells. Notably, the association between DFS and membrane hENT‐1 was dependent on the number of gemcitabine cycles (one to two cycles: HR 0.96, 95% CI 0.34–2.68; three to four cycles: HR 0.99, 95% CI 0.34–2.90; five to six cycles: HR 0.27, 95% CI 0.10–0.77). Conclusion. hENT‐1 localization on tumor cell membrane may predict response to adjuvant gemcitabine in CC patients receiving more than four cycles of chemotherapy. Further prospective randomized trials on larger populations are required to confirm these preliminary results, so that optimal gemcitabine‐based chemotherapy may be tailored for CC patients in the adjuvant setting. Implications for Practice: Gemcitabine is becoming an increasingly used adjuvant modality in cholangiocarcinoma (CC), but limited data are available on predictive biomarkers of response. In this study, patients receiving more than four cycles of adjuvant gemcitabine and harboring Human equilibrative nucleoside transporter 1 (hENT‐1, the major transporter involved in gemcitabine intracellular uptake) on tumor cell membrane had a longer disease‐free survival compared with patients negative or positive for hENT‐1 only in the cytoplasm of tumor cells. Overall these results may lay the basis for further prospective randomized trials based on a larger population of patients and may prove useful for tailoring appropriate gemcitabine‐based chemotherapy for CC patients in the adjuvant setting. In patients with resected cholangiocarcinoma undergoing treatment with adjuvant gemcitabine, human equilibrative nucleoside transporter 1 (hENT‐1) localization within tumor cells may be negative, positive in the cytoplasm only, or positive in both cytoplasm and membrane. Patients with hENT‐1 in membrane had longer disease‐free survival than the other groups, and the prediction was stronger with more cycles of gemcitabine. BACKGROUNDThe use of gemcitabine as an adjuvant modality for cholangiocarcinoma (CC) is increasing, but limited data are available on predictive biomarkers of response. Human equilibrative nucleoside transporter 1 (hENT-1) is the major transporter involved in gemcitabine intracellular uptake. This study investigated the putative predictive role of hENT-1 localization in tumor cells of CC patients undergoing treatment with adjuvant gemcitabine.METHODSSeventy-one consecutive patients with resected CC receiving adjuvant gemcitabine at our center were retrospectively analyzed by immunohistochemistry for hENT-1 localization in tumor cells. The main outcome measure was disease-free survival (DFS). Hazard ratios (HRs) of relapse and associated 95% confidence intervals (CIs) were obtained from proportional hazards regression models stratified on quintiles of propensity score.RESULTSTwenty-three (32.4%) cases were negative for hENT-1, 22 (31.0%) were positive in the cytoplasm only, and 26 (36.6%) showed concomitant cytoplasm/membrane staining. Patients with membrane hENT-1 had a longer DFS (HR 0.49, 95% CI 0.24-0.99, p = .046) than those who were negative or positive only in the cytoplasm of tumor cells. Notably, the association between DFS and membrane hENT-1 was dependent on the number of gemcitabine cycles (one to two cycles: HR 0.96, 95% CI 0.34-2.68; three to four cycles: HR 0.99, 95% CI 0.34-2.90; five to six cycles: HR 0.27, 95% CI 0.10-0.77).CONCLUSIONhENT-1 localization on tumor cell membrane may predict response to adjuvant gemcitabine in CC patients receiving more than four cycles of chemotherapy. Further prospective randomized trials on larger populations are required to confirm these preliminary results, so that optimal gemcitabine-based chemotherapy may be tailored for CC patients in the adjuvant setting.IMPLICATIONS FOR PRACTICEGemcitabine is becoming an increasingly used adjuvant modality in cholangiocarcinoma (CC), but limited data are available on predictive biomarkers of response. In this study, patients receiving more than four cycles of adjuvant gemcitabine and harboring Human equilibrative nucleoside transporter 1 (hENT-1, the major transporter involved in gemcitabine intracellular uptake) on tumor cell membrane had a longer disease-free survival compared with patients negative or positive for hENT-1 only in the cytoplasm of tumor cells. Overall these results may lay the basis for further prospective randomized trials based on a larger population of patients and may prove useful for tailoring appropriate gemcitabine-based chemotherapy for CC patients in the adjuvant setting. The use of gemcitabine as an adjuvant modality for cholangiocarcinoma (CC) is increasing, but limited data are available on predictive biomarkers of response. Human equilibrative nucleoside transporter 1 (hENT-1) is the major transporter involved in gemcitabine intracellular uptake. This study investigated the putative predictive role of hENT-1 localization in tumor cells of CC patients undergoing treatment with adjuvant gemcitabine. Seventy-one consecutive patients with resected CC receiving adjuvant gemcitabine at our center were retrospectively analyzed by immunohistochemistry for hENT-1 localization in tumor cells. The main outcome measure was disease-free survival (DFS). Hazard ratios (HRs) of relapse and associated 95% confidence intervals (CIs) were obtained from proportional hazards regression models stratified on quintiles of propensity score. Twenty-three (32.4%) cases were negative for hENT-1, 22 (31.0%) were positive in the cytoplasm only, and 26 (36.6%) showed concomitant cytoplasm/membrane staining. Patients with membrane hENT-1 had a longer DFS (HR 0.49, 95% CI 0.24-0.99, p = .046) than those who were negative or positive only in the cytoplasm of tumor cells. Notably, the association between DFS and membrane hENT-1 was dependent on the number of gemcitabine cycles (one to two cycles: HR 0.96, 95% CI 0.34-2.68; three to four cycles: HR 0.99, 95% CI 0.34-2.90; five to six cycles: HR 0.27, 95% CI 0.10-0.77). hENT-1 localization on tumor cell membrane may predict response to adjuvant gemcitabine in CC patients receiving more than four cycles of chemotherapy. Further prospective randomized trials on larger populations are required to confirm these preliminary results, so that optimal gemcitabine-based chemotherapy may be tailored for CC patients in the adjuvant setting. Gemcitabine is becoming an increasingly used adjuvant modality in cholangiocarcinoma (CC), but limited data are available on predictive biomarkers of response. In this study, patients receiving more than four cycles of adjuvant gemcitabine and harboring Human equilibrative nucleoside transporter 1 (hENT-1, the major transporter involved in gemcitabine intracellular uptake) on tumor cell membrane had a longer disease-free survival compared with patients negative or positive for hENT-1 only in the cytoplasm of tumor cells. Overall these results may lay the basis for further prospective randomized trials based on a larger population of patients and may prove useful for tailoring appropriate gemcitabine-based chemotherapy for CC patients in the adjuvant setting. |
Author | Lorenzo, Stefania Vasile, Enrico Pinna, Antonio D. Deserti, Marzia Silvestris, Nicola Pantaleo, Maria A. Aprile, Guiseppe Frega, Giorgio Santini, Daniele Lonardi, Sara Garajova, Ingrid Fornaro, Lorenzo Brandi, Giovanni D'Errico‐Grigioni, Antonietta Farioli, Andrea Degiovanni, Alessio Cereda, Stefano Biasco, Guido Palloni, Andrea Vasuri, Francesco Cescon, Matteo Barbera, Maria A. Di Marco, Mariacristina Tavolari, Simona Ercolani, Giorgio Leone, Francesco Cucchetti, Alessandro |
Author_xml | – sequence: 1 givenname: Giovanni surname: Brandi fullname: Brandi, Giovanni email: giovanni.brandi@unibo.it – sequence: 2 givenname: Marzia surname: Deserti fullname: Deserti, Marzia – sequence: 3 givenname: Francesco surname: Vasuri fullname: Vasuri, Francesco – sequence: 4 givenname: Andrea surname: Farioli fullname: Farioli, Andrea – sequence: 5 givenname: Alessio surname: Degiovanni fullname: Degiovanni, Alessio – sequence: 6 givenname: Andrea surname: Palloni fullname: Palloni, Andrea – sequence: 7 givenname: Giorgio surname: Frega fullname: Frega, Giorgio – sequence: 8 givenname: Maria A. surname: Barbera fullname: Barbera, Maria A. – sequence: 9 givenname: Stefania surname: Lorenzo fullname: Lorenzo, Stefania – sequence: 10 givenname: Ingrid surname: Garajova fullname: Garajova, Ingrid – sequence: 11 givenname: Mariacristina surname: Di Marco fullname: Di Marco, Mariacristina – sequence: 12 givenname: Antonio D. surname: Pinna fullname: Pinna, Antonio D. – sequence: 13 givenname: Matteo surname: Cescon fullname: Cescon, Matteo – sequence: 14 givenname: Alessandro surname: Cucchetti fullname: Cucchetti, Alessandro – sequence: 15 givenname: Giorgio surname: Ercolani fullname: Ercolani, Giorgio – sequence: 16 givenname: Antonietta surname: D'Errico‐Grigioni fullname: D'Errico‐Grigioni, Antonietta – sequence: 17 givenname: Maria A. surname: Pantaleo fullname: Pantaleo, Maria A. – sequence: 18 givenname: Guido surname: Biasco fullname: Biasco, Guido – sequence: 19 givenname: Simona surname: Tavolari fullname: Tavolari, Simona – sequence: 21 givenname: Guiseppe surname: Aprile fullname: Aprile, Guiseppe – sequence: 22 givenname: Stefano surname: Cereda fullname: Cereda, Stefano – sequence: 23 givenname: Lorenzo surname: Fornaro fullname: Fornaro, Lorenzo – sequence: 24 givenname: Francesco surname: Leone fullname: Leone, Francesco – sequence: 25 givenname: Sara surname: Lonardi fullname: Lonardi, Sara – sequence: 26 givenname: Daniele surname: Santini fullname: Santini, Daniele – sequence: 27 givenname: Nicola surname: Silvestris fullname: Silvestris, Nicola – sequence: 28 givenname: Enrico surname: Vasile fullname: Vasile, Enrico |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27032872$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkc1u1DAUhS1URNuBVwAv2aT4J4njBUjVqLRI006FBomd5Tg3M64Se2o7rYY34i3xaEpFd6x8JX_nnqtzTtGR8w4Q-kDJGa15-SltwDvjB7-2MZ0xQquC8Kp-hU5oVcqilOTnUZ5JwwtBK3mMTmO8IxmTnL1Bx0wQzhrBTtDvaxjboB3ghTd6sL90st5h3-OradQOX9xPdrCZSPYB8M1kBvDRdoBXWRS3PiQImGLr8GoafcBzGIaIr_UO3wborEn4O2TMRcDJ4_PubnrQLuFLGI1NurXZOGszAyZBh-cbP2i3tvmWYKzzo8a32Rpcim_R614PEd49vTP04-vFan5VLJaX3-bni8JUXJBCV7JtWVdKClD2bdXwWlICtJHAq64yrG_aRuiuBq2hop2QwkioZctZL0XN-Qx9OezdTu0IncneQQ9qG-yow055bdXLH2c3au0fVNnUlOeAZ-jj04Lg7yeISY02mpxLTtlPUVHRNIwJRvaoOKAm-BgD9M82lKh90epF0WpftNoXnZXv_73yWfe32Qx8PgCPdoDd_-5Vy5v5ktSE8D_218RV |
CitedBy_id | crossref_primary_10_1016_j_ejca_2018_11_005 crossref_primary_10_1016_j_biomaterials_2019_04_005 crossref_primary_10_3390_cells9020498 crossref_primary_10_18632_oncotarget_21624 crossref_primary_10_1038_s41416_020_0987_3 crossref_primary_10_1002_lci2_39 crossref_primary_10_3390_cancers13102358 crossref_primary_10_1007_s00280_020_04080_6 crossref_primary_10_2147_CMAR_S465098 crossref_primary_10_1634_theoncologist_2016_0262 crossref_primary_10_1016_j_critrevonc_2019_06_001 crossref_primary_10_1016_j_ejca_2016_12_032 crossref_primary_10_1200_PO_18_00240 crossref_primary_10_1080_13543784_2021_1916912 crossref_primary_10_1016_j_ijscr_2023_108819 crossref_primary_10_1634_theoncologist_2016_0286 crossref_primary_10_1111_jgh_14477 crossref_primary_10_3390_cancers12113206 crossref_primary_10_3892_ol_2024_14503 crossref_primary_10_1136_gutjnl_2022_327099 crossref_primary_10_18632_oncotarget_19037 |
Cites_doi | 10.1016/S0140-6736(13)61903-0 10.1056/NEJMoa0908721 10.1093/oxfordjournals.aje.a116813 10.1111/j.1349-7006.2010.01837.x 10.1634/theoncologist.9-1-43 10.1016/j.ejca.2011.11.006 10.2307/2986270 10.1097/SLA.0b013e3182536a42 10.1200/JCO.2011.40.5381 10.1111/apt.12900 10.1007/s00534-008-0015-0 10.1016/j.bbamem.2009.08.003 10.1016/j.dld.2015.11.017 10.2307/2531396 10.1111/j.1349-7006.2007.00581.x 10.3390/cancers2042044 10.2174/156800911793743600 10.1245/s10434-010-1325-4 10.1634/theoncologist.2007-0215 10.1200/JCO.2013.50.7657 10.1016/j.yexcr.2011.03.008 10.1186/1477-7819-11-117 10.1093/annonc/mdm576 |
ContentType | Journal Article |
Contributor | Vasile, Enrico Santini, Daniele Lonardi, Sara Silvestris, Nicola Fornaro, Lorenzo Leone, Francesco Aprile, Guiseppe Cereda, Stefano |
Contributor_xml | – sequence: 1 givenname: Guiseppe surname: Aprile fullname: Aprile, Guiseppe – sequence: 2 givenname: Stefano surname: Cereda fullname: Cereda, Stefano – sequence: 3 givenname: Lorenzo surname: Fornaro fullname: Fornaro, Lorenzo – sequence: 4 givenname: Francesco surname: Leone fullname: Leone, Francesco – sequence: 5 givenname: Sara surname: Lonardi fullname: Lonardi, Sara – sequence: 6 givenname: Daniele surname: Santini fullname: Santini, Daniele – sequence: 7 givenname: Nicola surname: Silvestris fullname: Silvestris, Nicola – sequence: 8 givenname: Enrico surname: Vasile fullname: Vasile, Enrico |
Copyright | 2016 AlphaMed Press AlphaMed Press. AlphaMed Press 2016 |
Copyright_xml | – notice: 2016 AlphaMed Press – notice: AlphaMed Press. – notice: AlphaMed Press 2016 |
CorporateAuthor | G.I.CO. (Gruppo Italiano Colangiocarcinoma) on behalf of G.I.CO. (Gruppo Italiano Colangiocarcinoma) |
CorporateAuthor_xml | – name: G.I.CO. (Gruppo Italiano Colangiocarcinoma) – name: on behalf of G.I.CO. (Gruppo Italiano Colangiocarcinoma) |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1634/theoncologist.2015-0356 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Predictive Role of hENT-1 in CC |
EISSN | 1549-490X |
EndPage | 607 |
ExternalDocumentID | 10_1634_theoncologist_2015_0356 27032872 ONCO0600 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Fondazione Cassa di Risparmio di Bologna – fundername: Fundamental Oriented Research funderid: RFO 2013 |
GroupedDBID | --- 0R~ 123 18M 1OC 24P 2WC 36B 4.4 53G 5VS AAPXW AAVAP AAWTL AAZKR ABPTD ABXVV ACXQS ADBBV ADXAS AEGXH AENEX AJAOE ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BFHJK CS3 DCZOG DIK DU5 E3Z EBD EBS EJD EMB EMOBN F5P FRP GROUPED_DOAJ GX1 H13 HYE HZ~ IAO IHR INH LUTES LYRES O9- OK1 P2P P2W RAO RHF RHI ROL ROX RPM SUPJJ SV3 TOX TR2 UDS W2D W8F WIN WOHZO WOQ WOW XSB ZZTAW CGR CUY CVF ECM EIF ITC NPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c5370-a59bb2d491ee4fb5836910e189e35d5c2f8b87ad6eaae51d797c9e69b32f97633 |
IEDL.DBID | RPM |
ISSN | 1083-7159 |
IngestDate | Tue Sep 17 21:11:37 EDT 2024 Sat Aug 17 02:55:41 EDT 2024 Fri Aug 23 01:24:08 EDT 2024 Sat Sep 28 08:48:13 EDT 2024 Sat Aug 24 00:38:37 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Human equilibrative nucleoside transporter 1 Predictive biomarkers of response to chemotherapy Adjuvant gemcitabine Cholangiocarcinoma |
Language | English |
License | AlphaMed Press. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5370-a59bb2d491ee4fb5836910e189e35d5c2f8b87ad6eaae51d797c9e69b32f97633 |
Notes | Disclosures of potential conflicts of interest may be found at the end of this article. Contributed equally. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1634/theoncologist.2015-0356 |
PMID | 27032872 |
PQID | 1788227209 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4861359 proquest_miscellaneous_1788227209 crossref_primary_10_1634_theoncologist_2015_0356 pubmed_primary_27032872 wiley_primary_10_1634_theoncologist_2015_0356_ONCO0600 |
PublicationCentury | 2000 |
PublicationDate | May 2016 |
PublicationDateYYYYMMDD | 2016-05-01 |
PublicationDate_xml | – month: 05 year: 2016 text: May 2016 |
PublicationDecade | 2010 |
PublicationPlace | Durham, NC, USA |
PublicationPlace_xml | – name: Durham, NC, USA – name: United States |
PublicationTitle | The oncologist (Dayton, Ohio) |
PublicationTitleAlternate | Oncologist |
PublicationYear | 2016 |
Publisher | AlphaMed Press |
Publisher_xml | – name: AlphaMed Press |
References | 1984; 40 2009; 1788 2011; 317 2010 2008; 19 2004; 9 2010; 223 2011; 11 2010; 362 2008; 13 2014; 40 2007; 98 2011; 18 2012; 30 1994; 43 2015; 48 2011; 102 2012; 256 2013; 11 2012; 48 2010; 2 2014; 383 2014; 7 1993; 138 2009; 16 2014; 32 26769568 - Dig Liver Dis. 2016 Mar;48(3):231-41 25664003 - Int J Clin Exp Med. 2014 Dec 15;7(12):5041-9 19699178 - Biochim Biophys Acta. 2009 Oct;1788(10):2326-34 20375404 - N Engl J Med. 2010 Apr 8;362(14):1273-81 24581682 - Lancet. 2014 Jun 21;383(9935):2168-79 6487727 - Biometrics. 1984 Jun;40(2):437-43 24419109 - J Clin Oncol. 2014 Feb 20;32(6):504-12 21205085 - Cancer Sci. 2011 Mar;102(3):622-9 27807304 - Oncologist. 2016 Dec;21(12 ):e4 18378536 - Oncologist. 2008 Mar;13(3):261-76 20082300 - J Cell Physiol. 2010 May;223(2):384-8 20578980 - Curr Cancer Drug Targets. 2011 Jan;11(1):123-9 22580938 - Ann Surg. 2012 Aug;256(2):288-96 27807301 - Oncologist. 2016 Dec;21(12 ):e5-e6 14755014 - Oncologist. 2004;9(1):43-57 25099956 - Aliment Pharmacol Ther. 2014 Oct;40(7):759-70 8256780 - Am J Epidemiol. 1993 Dec 1;138(11):923-36 24281217 - Cancers (Basel). 2010 Dec 02;2(4):2044-54 17711502 - Cancer Sci. 2007 Oct;98(10):1633-7 21402067 - Exp Cell Res. 2011 Jul 1;317(11):1567-79 19110652 - J Hepatobiliary Pancreat Surg. 2009;16(1):1-7 22529261 - J Clin Oncol. 2012 Jun 1;30(16):1934-40 23710668 - World J Surg Oncol. 2013;11:117 18187485 - Ann Oncol. 2008 Apr;19(4):724-8 22137164 - Eur J Cancer. 2012 May;48(7):990-6 20945107 - Ann Surg Oncol. 2011 Mar;18(3):651-8 Nivillac (2021122309533791000_B18) 2009; 1788 Maldonado (2021122309533791000_B21) 1993; 138 Murata (2021122309533791000_B15) 2013; 11 Spratlin (2021122309533791000_B11) 2010; 2 Bosman (2021122309533791000_B22) 2010 Nishio (2021122309533791000_B23) 2011; 102 Santini (2021122309533791000_B26) 2010; 223 Nivillac (2021122309533791000_B24) 2011; 317 Endo (2021122309533791000_B17) 2007; 98 Brandi (2021122309533791000_B5) 2015; 48 Anderson (2021122309533791000_B2) 2004; 9 Murakami (2021122309533791000_B4) 2011; 18 Veltkamp (2021122309533791000_B10) 2008; 13 Santini (2021122309533791000_B12) 2011; 11 Kobayashi (2021122309533791000_B14) 2012; 256 Horgan (2021122309533791000_B7) 2012; 30 Valle (2021122309533791000_B8) 2010; 362 Zhu (2021122309533791000_B9) 2014; 40 Miyakawa (2021122309533791000_B3) 2009; 16 Borbath (2021122309533791000_B13) 2012; 48 Royston (2021122309533791000_B20) 1994; 43 Deng (2021122309533791000_B16) 2014; 7 Rosenbaum (2021122309533791000_B19) 1984; 40 Razumilava (2021122309533791000_B1) 2014; 383 2021122309533791000_B6 Valle (2021122309533791000_B25) 2014; 32 Santini (2021122309533791000_B27) 2008; 19 |
References_xml | – volume: 2 start-page: 2044 year: 2010 end-page: 2054 article-title: Human equilibrative nucleoside transporter 1 (hENT1) in pancreatic adenocarcinoma: Towards individualized treatment decisions publication-title: Cancers (Basel) – volume: 48 start-page: 990 year: 2012 end-page: 996 article-title: Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma publication-title: Eur J Cancer – volume: 256 start-page: 288 year: 2012 end-page: 296 article-title: Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine‐based adjuvant chemotherapy after surgical resection publication-title: Ann Surg – volume: 9 start-page: 43 year: 2004 end-page: 57 article-title: Diagnosis and treatment of cholangiocarcinoma publication-title: The Oncologist – volume: 7 start-page: 5041 year: 2014 end-page: 5049 article-title: Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer publication-title: Int J Clin Exp Med – volume: 102 start-page: 622 year: 2011 end-page: 629 article-title: Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd) publication-title: Cancer Sci – volume: 11 start-page: 123 year: 2011 end-page: 129 article-title: Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC) publication-title: Curr Cancer Drug Targets – volume: 32 start-page: 504 year: 2014 end-page: 512 article-title: Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: Ongoing lessons from the ESPAC‐3 study publication-title: J Clin Oncol – volume: 362 start-page: 1273 year: 2010 end-page: 1281 article-title: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer publication-title: N Engl J Med – volume: 30 start-page: 1934 year: 2012 end-page: 1940 article-title: Adjuvant therapy in the treatment of biliary tract cancer: A systematic review and meta‐analysis publication-title: J Clin Oncol – volume: 317 start-page: 1567 year: 2011 end-page: 1579 article-title: The life cycle of human equilibrative nucleoside transporter 1: From ER export to degradation publication-title: Exp Cell Res – volume: 138 start-page: 923 year: 1993 end-page: 936 article-title: Simulation study of confounder‐selection strategies publication-title: Am J Epidemiol – volume: 40 start-page: 759 year: 2014 end-page: 770 article-title: Systematic review with network meta‐analysis: Adjuvant therapy for resected biliary tract cancer publication-title: Aliment Pharmacol Ther – volume: 16 start-page: 1 year: 2009 end-page: 7 article-title: Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan publication-title: J Hepatobiliary Pancreat Surg – volume: 19 start-page: 724 year: 2008 end-page: 728 article-title: Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer publication-title: Ann Oncol – year: 2010 – volume: 43 start-page: 429 year: 1994 end-page: 467 article-title: Regression using fractional polynomials of continuous covariates: Parsimonious parametric modelling publication-title: Appl Stat – volume: 18 start-page: 651 year: 2011 end-page: 658 article-title: Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma publication-title: Ann Surg Oncol – volume: 98 start-page: 1633 year: 2007 end-page: 1637 article-title: Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides publication-title: Cancer Sci – volume: 1788 start-page: 2326 year: 2009 end-page: 2334 article-title: Disrupted plasma membrane localization and loss of function reveal regions of human equilibrative nucleoside transporter 1 involved in structural integrity and activity publication-title: Biochim Biophys Acta – volume: 48 start-page: 231 year: 2015 end-page: 241 article-title: Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms: A review of the literature and a long‐standing experience of a referral center publication-title: Dig Liver Dis – volume: 11 start-page: 117 year: 2013 article-title: Prognostic predictive values of gemcitabine sensitivity‐related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone publication-title: World J Surg Oncol – volume: 383 start-page: 2168 year: 2014 end-page: 2179 article-title: Cholangiocarcinoma publication-title: Lancet – volume: 40 start-page: 437 year: 1984 end-page: 443 article-title: Difficulties with regression analyses of age‐adjusted rates publication-title: Biometrics – volume: 13 start-page: 261 year: 2008 end-page: 276 article-title: Prolonged versus standard gemcitabine infusion: Translation of molecular pharmacology to new treatment strategy publication-title: The Oncologist – volume: 223 start-page: 384 year: 2010 end-page: 388 article-title: Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer publication-title: J Cell Physiol – volume: 383 start-page: 2168 year: 2014 ident: 2021122309533791000_B1 article-title: Cholangiocarcinoma publication-title: Lancet doi: 10.1016/S0140-6736(13)61903-0 contributor: fullname: Razumilava – volume: 362 start-page: 1273 year: 2010 ident: 2021122309533791000_B8 article-title: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa0908721 contributor: fullname: Valle – volume: 138 start-page: 923 year: 1993 ident: 2021122309533791000_B21 article-title: Simulation study of confounder-selection strategies publication-title: Am J Epidemiol doi: 10.1093/oxfordjournals.aje.a116813 contributor: fullname: Maldonado – volume: 102 start-page: 622 year: 2011 ident: 2021122309533791000_B23 article-title: Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd) publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2010.01837.x contributor: fullname: Nishio – volume: 9 start-page: 43 year: 2004 ident: 2021122309533791000_B2 article-title: Diagnosis and treatment of cholangiocarcinoma publication-title: The Oncologist doi: 10.1634/theoncologist.9-1-43 contributor: fullname: Anderson – volume: 48 start-page: 990 year: 2012 ident: 2021122309533791000_B13 article-title: Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma publication-title: Eur J Cancer doi: 10.1016/j.ejca.2011.11.006 contributor: fullname: Borbath – volume: 43 start-page: 429 year: 1994 ident: 2021122309533791000_B20 article-title: Regression using fractional polynomials of continuous covariates: Parsimonious parametric modelling publication-title: Appl Stat doi: 10.2307/2986270 contributor: fullname: Royston – volume: 256 start-page: 288 year: 2012 ident: 2021122309533791000_B14 article-title: Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection publication-title: Ann Surg doi: 10.1097/SLA.0b013e3182536a42 contributor: fullname: Kobayashi – volume: 30 start-page: 1934 year: 2012 ident: 2021122309533791000_B7 article-title: Adjuvant therapy in the treatment of biliary tract cancer: A systematic review and meta-analysis publication-title: J Clin Oncol doi: 10.1200/JCO.2011.40.5381 contributor: fullname: Horgan – volume: 40 start-page: 759 year: 2014 ident: 2021122309533791000_B9 article-title: Systematic review with network meta-analysis: Adjuvant therapy for resected biliary tract cancer publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.12900 contributor: fullname: Zhu – volume: 7 start-page: 5041 year: 2014 ident: 2021122309533791000_B16 article-title: Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer publication-title: Int J Clin Exp Med contributor: fullname: Deng – volume: 16 start-page: 1 year: 2009 ident: 2021122309533791000_B3 article-title: Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan publication-title: J Hepatobiliary Pancreat Surg doi: 10.1007/s00534-008-0015-0 contributor: fullname: Miyakawa – volume-title: World Health Organization Classification of Tumours of the Digestive System year: 2010 ident: 2021122309533791000_B22 contributor: fullname: Bosman – volume: 1788 start-page: 2326 year: 2009 ident: 2021122309533791000_B18 article-title: Disrupted plasma membrane localization and loss of function reveal regions of human equilibrative nucleoside transporter 1 involved in structural integrity and activity publication-title: Biochim Biophys Acta doi: 10.1016/j.bbamem.2009.08.003 contributor: fullname: Nivillac – volume: 48 start-page: 231 year: 2015 ident: 2021122309533791000_B5 article-title: Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms: A review of the literature and a long-standing experience of a referral center publication-title: Dig Liver Dis doi: 10.1016/j.dld.2015.11.017 contributor: fullname: Brandi – volume-title: National Comprehensive Cancer Network-Hepatobiliary Cancers. 2012 ident: 2021122309533791000_B6 – volume: 223 start-page: 384 year: 2010 ident: 2021122309533791000_B26 article-title: Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer publication-title: J Cell Physiol contributor: fullname: Santini – volume: 40 start-page: 437 year: 1984 ident: 2021122309533791000_B19 article-title: Difficulties with regression analyses of age-adjusted rates publication-title: Biometrics doi: 10.2307/2531396 contributor: fullname: Rosenbaum – volume: 98 start-page: 1633 year: 2007 ident: 2021122309533791000_B17 article-title: Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2007.00581.x contributor: fullname: Endo – volume: 2 start-page: 2044 year: 2010 ident: 2021122309533791000_B11 article-title: Human equilibrative nucleoside transporter 1 (hENT1) in pancreatic adenocarcinoma: Towards individualized treatment decisions publication-title: Cancers (Basel) doi: 10.3390/cancers2042044 contributor: fullname: Spratlin – volume: 11 start-page: 123 year: 2011 ident: 2021122309533791000_B12 article-title: Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC) publication-title: Curr Cancer Drug Targets doi: 10.2174/156800911793743600 contributor: fullname: Santini – volume: 18 start-page: 651 year: 2011 ident: 2021122309533791000_B4 article-title: Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma publication-title: Ann Surg Oncol doi: 10.1245/s10434-010-1325-4 contributor: fullname: Murakami – volume: 13 start-page: 261 year: 2008 ident: 2021122309533791000_B10 article-title: Prolonged versus standard gemcitabine infusion: Translation of molecular pharmacology to new treatment strategy publication-title: The Oncologist doi: 10.1634/theoncologist.2007-0215 contributor: fullname: Veltkamp – volume: 32 start-page: 504 year: 2014 ident: 2021122309533791000_B25 article-title: Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: Ongoing lessons from the ESPAC-3 study publication-title: J Clin Oncol doi: 10.1200/JCO.2013.50.7657 contributor: fullname: Valle – volume: 317 start-page: 1567 year: 2011 ident: 2021122309533791000_B24 article-title: The life cycle of human equilibrative nucleoside transporter 1: From ER export to degradation publication-title: Exp Cell Res doi: 10.1016/j.yexcr.2011.03.008 contributor: fullname: Nivillac – volume: 11 start-page: 117 year: 2013 ident: 2021122309533791000_B15 article-title: Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone publication-title: World J Surg Oncol doi: 10.1186/1477-7819-11-117 contributor: fullname: Murata – volume: 19 start-page: 724 year: 2008 ident: 2021122309533791000_B27 article-title: Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdm576 contributor: fullname: Santini |
SSID | ssj0015932 |
Score | 2.3580837 |
Snippet | Background.
The use of gemcitabine as an adjuvant modality for cholangiocarcinoma (CC) is increasing, but limited data are available on predictive biomarkers... The use of gemcitabine as an adjuvant modality for cholangiocarcinoma (CC) is increasing, but limited data are available on predictive biomarkers of response.... Abstract Background. The use of gemcitabine as an adjuvant modality for cholangiocarcinoma (CC) is increasing, but limited data are available on predictive... BACKGROUNDThe use of gemcitabine as an adjuvant modality for cholangiocarcinoma (CC) is increasing, but limited data are available on predictive biomarkers of... In patients with resected cholangiocarcinoma undergoing treatment with adjuvant gemcitabine, human equilibrative nucleoside transporter 1 (hENT-1) localization... |
SourceID | pubmedcentral proquest crossref pubmed wiley |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 600 |
SubjectTerms | Adjuvant gemcitabine Aged Antimetabolites, Antineoplastic - therapeutic use Bile Duct Neoplasms - chemistry Bile Duct Neoplasms - drug therapy Bile Duct Neoplasms - mortality Bile Duct Neoplasms - surgery Chemotherapy, Adjuvant Cholangiocarcinoma Cholangiocarcinoma - chemistry Cholangiocarcinoma - drug therapy Cholangiocarcinoma - mortality Cholangiocarcinoma - surgery Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Disease-Free Survival Equilibrative Nucleoside Transporter 1 - analysis Female Hepatobiliary Human equilibrative nucleoside transporter 1 Humans Male Middle Aged Predictive biomarkers of response to chemotherapy |
Title | Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1634%2Ftheoncologist.2015-0356 https://www.ncbi.nlm.nih.gov/pubmed/27032872 https://search.proquest.com/docview/1788227209 https://pubmed.ncbi.nlm.nih.gov/PMC4861359 |
Volume | 21 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb5wwELaSHKpeqr5L01au1CtZwPh1jFDSqCq7q2oj7Q3Z2LREC6QsHPqT8i875pF2lUvVCxICzMjfGH_DfB4j9IkJS0zECl8Kqv2Y59JXSgU-zYXNg9DExrqFwumSXV3HX7Z0e4TovBZmEO3nujyrd9VZXf4YtJW3Vb6YdWKLdZrEAiYhKhfH6JgTMofoU-qASjKmOAXxOZxNoi5G4oVbG1gPxaChC52si_oBoW4Xo4i7unI8OpydHlDOh8rJvxntMCVdPkVPJi6Jz0ebn6EjWz9Hj9IpW_4C3aW2gmC4tvirm7GmFZe4KfDw6x5f_OzLIVx2nzy8dJWNG7d7J_5T8bzFIS5rvOmrpsWJ3e32OFW_8Lp1L-nwt1Fha3HX4HNz0wMt7_BnW-VlpyDktu5Zp-3LgdfixIXR9fcSbGnBwKZSeD1Wdd2_RNeXF5vkyp-2ZvBzSnjgKyq1jkwsQ2vjQlNBGPAOGwppCTU0jwqhBVeGWaUsDQ2X4AWWSU2iAggQIa_QSd3U9g3COmeGxsYp7YpYB0pRwEWEVEcQulHDPRTMkGS3YwWOzEUuAGh2AGjmAM0coB76OEOXwWhxKRDo66bfZyFE_JFLPUsPvR6hvG909gEP8QOQ729wlbgPr4CDDhW5J4f0EBvc4V_tzFbLZBUA5Xz73688RY-hOTZKMN-hk67t7XugSZ3-MAwLOG5W29804xg4 |
link.rule.ids | 230,315,733,786,790,891,27957,27958,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLVKkaAb3pTwNBLbzCRxHDvLKmoZYDIdoSnqLvIrEJgkZSZZwB_xl1znURi6AZZREj_i4_hc3eNjhF5F3BAdRLkbcyrdkKnYFUJ4LlXcKM_XoTZ2o3C6iGZn4dtzer6H6LgXphPtK1lMqnU5qYpPnbbyolTTUSc2XaZJyGERovH0GroO8zVgY5A-JA9oTPokJycug6tB1hWRcGp3B1adHTR8RCvsoq5HqD3HKGDWWY4Fu-vTFdJ5VTv5O6ftFqWT2-jD2J1ei_Jl0jZyor7_4fT4z_29g24NNBUf9bfvoj1T3UM30iERfx_9SE0JcXZl8NwuhsNmTlznuMsK4OOvbdFF4vZvihfWNLm2B4PiX2bqG-zjosKrtqw3ODHr9Ran4htebmwlDX7fi3cNbmp8pD-3wPgb_NqUqmgERPPGvmtlgwooM05shF59LKAtG2hgXQq87A1jtw_Q2cnxKpm5w6kPrqKEea6gsZSBDmPfmDCXlJMIKI3xeWwI1VQFOZecCR0ZIQz1NYsBYCaKJQly4FaEPET7VV2ZRwhLFWkaaiviy0PpCUFhwLlPZQBRIdXMQd441tlFb-6R2aAIkJLtICWzSMksUhz0csREBhPRZlfgW9ftNvMZBCs2qx076LDHyGWhI7gcxHbQc_mANfnevQNY6My-h7F3UNTh7G_bmZ0uklMP2Ozj_67yBbo5W6XzbP5m8e4JOoCio17p-RTtN5vWPAM21sjn3dz7Cf4TORg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLWgSBUb3pSUl5HYZvJwnMTLKnQo0ExHqJUqNpFfgcAkmWaSBfwRf8l1HqVDN6jLKE5sx8fxubrHxwi9DWNNlB_mNoupsINIMptz7tpUxlq6ngqUNhuF00V4dBZ8PKfnV4766kX7UhSzalXOquJbr61cl9KZdGLOMk2CGBYhypy1yp3b6A7MWZ9NgfqYQKCMDInOmNgRXI3SrpAEjtkhWPWW0PAhjbiL2i6h5iwjPzLucpG_vUZdI57X9ZNXeW2_MM3voy9TlwY9yo9Z14qZ_PWP2-ON-vwA3RvpKj4YijxEt3T1CO2mY0L-Mfqd6hLi7UrjY7Mojps6cZ3jPjuADy-6oo_IzV8VL4x5cm0OCMV_TdUb7OGiwqddWTc40avVBqf8J142ppIWfx5EvBq3NT5Q3ztg_i1-r0tZtByiem2eNfJBCdQZJyZSr74W0JYGGliXHC8H49jNE3Q2PzxNjuzx9AdbUhK5NqdMCF8FzNM6yAWNSQjURnsx04QqKv08FnHEVag519RTEQOg6ZAJ4ufAsQh5inaqutLPEBYyVDRQRsyXB8LlnMKgxx4VPkSHVEUWcqfxztaDyUdmgiNAS7aFlsygJTNosdCbCRcZTEiTZYFvXXebzIsgaDHZbWahvQEnly-dAGahaAtBlwWM2ff2HcBDb_o9jr-Fwh5r_9vO7GSRnLjAavdvXOVrtLt8N8-OPyw-PUd34c3hIPh8gXbaptMvgZS14lU__f4AmNM7mA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Membrane+Localization+of+Human+Equilibrative+Nucleoside+Transporter+1+in+Tumor+Cells+May+Predict+Response+to+Adjuvant+Gemcitabine+in+Resected+Cholangiocarcinoma+Patients&rft.jtitle=The+oncologist+%28Dayton%2C+Ohio%29&rft.au=Brandi%2C+Giovanni&rft.au=Deserti%2C+Marzia&rft.au=Vasuri%2C+Francesco&rft.au=Farioli%2C+Andrea&rft.date=2016-05-01&rft.issn=1083-7159&rft.eissn=1549-490X&rft.volume=21&rft.issue=5&rft.spage=600&rft.epage=607&rft_id=info:doi/10.1634%2Ftheoncologist.2015-0356&rft.externalDBID=n%2Fa&rft.externalDocID=10_1634_theoncologist_2015_0356 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1083-7159&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1083-7159&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1083-7159&client=summon |